Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of Interpharm...

Agreement Executed for Amneal Pharmaceuticals to Acquire the Assets of
Interpharm Holdings

PATERSON, N.J., April 24 /PRNewswire/ -- Amneal Pharmaceuticals, LLC is
pleased to announce the execution of an Asset Purchase Agreement for Amneal's
wholly-owned subsidiary, Amneal Pharmaceuticals of New York, LLC, to acquire
the assets, facilities and business of Interpharm. The acquisition includes
Interpharm's facilities on Long Island, New York as well as the intellectual
property including ANDA's, technology and processes.
Amneal will use its strong leadership and financial position to fully
realize the potential of Interpharm's powerful product line, ensure approval
of its well defined development pipeline and leverage the unique manufacturing
capabilities.
"Utilizing Amneal's financial strength, superb quality management, R&D and
manufacturing expertise with Interpharm's outstanding facilities, leading
market share and high value pipeline creates tremendous opportunities for
rapid growth and exceptional customer satisfaction," said Chintu Patel, CEO of
Amneal.
"Interpharm is excited about this acquisition of our assets. The
financial stability brought by Amneal will allow it to springboard its rapid
growth plans, and enhance the value to our loyal trading partners," added Jeff
Weiss, Interpharm's executive vice president of sales and marketing.
Amneal will list assets of over one hundred products approved or filed
with the USFDA and in development, controlled substance (C II-V) licensing and
manufacturing, hormonal production suite, high potency production suite, soft
gelatin capsules manufacturing, liquids manufacturing plant, 20 billion unit
oral solid capacity and expansive R&D centers in New Jersey, New York and
newly opened in India. Amneal president Chirag Patel comments, "This
acquisition of intellectual and tangible assets provides Amneal the ability to
accelerate its aggressive growth plans and rapidly broaden and deepen its
product portfolio, while staying committed to full vertical integration and
industry leading operations, R&D and Customer Service."
About Amneal Pharmaceuticals:
Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based
firm that develops, manufacturers and distributes generic pharmaceutical
products regulated and approved by the US FDA. Positioned as "Generic's New
Generation," the company utilizes diverse R&D and manufacturing expertise to
conceive breakthrough developments with lasting impact. Vigorous ANDA growth
and broad product acquisitions are key features of Amneal's strategic growth
plan, as is the company's commitment to building deep relationships with its
customer base. Amneal delivers superior service levels, quality products, and
dynamic value throughout the pharmaceutical industry.
SOURCE Amneal Pharmaceuticals, LLC

Jim Luce, Executive Vice President-Sales & Marketing, Amneal Pharmaceuticals,
LLC, +1-949-610-8018, Mobile +1-949-633-2293, Fax: +1-949-610-8218,
jim@amneal.com